| Ytd | -63.12% | |
| 1y | -29.93% |
| Open | 0.48 | Prev Close | 0.47 | Low | 0.47 | High | 0.49 | Mkt Cap | 15.90M |
| Vol | 18.87K | Avg Vol | 797.89K | EPS | -1.60 | P/E | -0.30 | Forward P/E | -3.75 |
| Beta | 0.29 | Short Ratio | 0.32 | Inst. Own | 2.87% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-16 | 50-d Avg | 0.52 | 200-d Avg | 0.76 | 1yr Est | 2.00 |
KTTA News
-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK In
-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK In
KTTA, NTRS, YEXT, AEHR and STT have been added to the Zacks Rank #1 (Strong Buy) List on July 20, 20
MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or t
-- Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, wit
-- Remains on track to release interim NF1 data update in Q4 2026 -- -- Additional dose levels and l
-- Company will engage with NF1 community following recent FDA Fast Track and Rare Pediatric Disease
Pasithea Therapeutics (KTTA) appears to have found support after losing some value lately, as indica
MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or t
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or th
MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or
Pasithea Therapeutics (NASDAQ: KTTA - Get Free Report) is projected to announce its results before t
Pasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conf
Pasithea Therapeutics (Nasdaq: KTTA) will present to Oppenheimer 36th Annual Healthcare Life Science
MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or t
MIAMI, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (
Extends cash runway through at least the first half of 2028 Led by Vivo Capital, Janus Henderson Inv
-- The ALS Association is the world's leading funder of amyotrophic lateral sclerosis (ALS) research
-- Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Coh
Pasithea Therapeutics Corp. (NASDAQ: KTTA - Get Free Report)'s stock price was down 29.6% during tra
On Thursday, 185 companies achieved new lows for the year.
On Monday, 89 stocks made new 52-week lows.
On Friday, 469 companies hit new 52-week lows.
On Monday, 198 companies hit new 52-week lows.
On Wednesday, 479 stocks made new 52-week lows.
During Friday's trading, 293 companies set new 52-week lows.
On Wednesday, 215 companies set new 52-week lows.
On Monday, 198 companies reached new 52-week lows.
During Tuesday's trading, 505 companies set new 52-week lows.
During Wednesday's morning trading, 400 companies set new 52-week lows.